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Abstract
The use of radioisotopes has a long history in biomedical science, and the technique of accelerator
mass spectrometry (AMS), an extremely sensitive nuclear physics technique for detection of very
low-abundant, stable and long-lived isotopes, has now revolutionized high-sensitivity isotope
detection in biomedical research, because it allows the direct determination of the amount of
isotope in a sample rather than measuring its decay, and thus the quantitative analysis of the fate of
the radiolabeled probes under the given conditions. Since AMS was first used in the early 90's for
the analysis of biological samples containing enriched 14C for toxicology and cancer research, the
biomedical applications of AMS to date range from in vitro to in vivo studies, including the studies of
1) toxicant and drug metabolism, 2) neuroscience, 3) pharmacokinetics, and 4) nutrition and
metabolism of endogenous molecules such as vitamins. In addition, a new drug development
concept that relies on the ultrasensitivity of AMS, known as human microdosing, is being used to
obtain early human metabolism information of candidate drugs. These various aspects of AMS are
reviewed and a perspective on future applications of AMS to biomedical research is provided.
Introduction
Accelerator mass spectrometry (AMS; see Figure 1 for AMS
schematic diagram) is an extremely sensitive nuclear
physics technique for detection of very low-abundant, sta-
ble and long-lived isotopes, initially developed in the
mid-70's as a method of determining isotope ratios for
geochronology and archaeological research [1,2]. The
technique utilizes a tandem van de Graaff accelerator in
order to generate the potential energy, allowing for sepa-
ration of elemental isotopes at the single atom level.
Therefore, AMS can be applied to quantitating the concen-
trations of long-lived radioisotopes, such as 14C, for which
decay counting is an inefficient method of quantitation
because of its relatively long half-life of 5760 years [3].
Much of this discussion concerns 14C because it is the pre-
dominant isotope for biomedical/bioanalytical probe
analysis. However, equivalent discussions refer equally
well with changes in chemistry [4], to several other long-
lived isotopes that can be quantitated by AMS: 3H, 10Be,
16Al, 36Cl, 41Ca, 56Ni, 99Tc, 129I, and 239Pu.
The sensitivity of AMS for radiocarbon can be emphasized
by its use in geochronology or carbon dating of historical
artefacts [1,2]. As widely known, small amounts of 14C are
constantly being formed from 14N by bombardment with
cosmic radiation in the upper atmosphere, and this for-
mation gives rise to 14CO2, and maintains the atmosphere
at a nearly constant radiocarbon concentration of about
1.2 × 10-10%  14C (primarily as CO2) [5-7]. Plants fix
atmospheric  14CO2, animals eat the plants and thus all
higher living organisms contain 14C in equilibrium. When
an organism dies, there is no longer any carbon exchange,
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and 14C decays over time. Thus, the 12C:14C ratio can be
correlated with the amount of time elapsed after an organ-
ism's death, which is the basis of carbon dating. Carbon
dating now extends beyond 50,000 years back in time [3].
The most conventional method for the measurement of
radioactivity for biomedical applications is liquid scintil-
lation counting (LSC), a process known as decay count-
ing. LSC, however, suffers from an innate insensitivity. In
fact, it takes over a billion atoms of 14C to generate an
average of only one disintegration per minute (dpm).
AMS, on the other hand, allows direct measurement of
12C and 14C atoms by physically separating them in an ion
beam [3]. Since the atoms are measured directly, without
a necessity to wait for a disintegration event to occur, AMS
is about six orders of magnitude more sensitive than LSC.
Nowadays, AMS is the method of choice for carbon dating
as well as other LCS-utilized biomedical research because
of the technique's sensitivity and precision. The workings
of an AMS instrument are outlined elsewhere [8-10].
The development of biomedical AMS
The use of radioisotopes has a long history in biomedical
science. Isotopic enrichment of xenobiotics with 14C is
routinely used as a method of following their metabolic
fate in both animals and humans, and a drug is typically
synthesized such that the natural abundance of 14C is
increased from the background level of 1.2 × 10-10% to
20% or even higher depending upon the compound. The
low energy β-radioactivity is then used to track the radi-
olabeled compound and its metabolites in biological
samples derived from laboratory animal or human stud-
ies. LSC has been generally used for a long time to detect,
follow and quantitate levels of radiotracer in such studies.
There are occasions, however, when the low sensitivity of
Schematic diagram of an accelerator mass spectrometry (AMS) Figure 1
Schematic diagram of an accelerator mass spectrometry (AMS). Cesium (Cs) sputter ion source (A) contains the 
wheel with the graphite samples under high vacuum. Atomic Cs vapor is produced from a heated Cs reservoir and sprayed on 
to a heated ionizer surface, producing Cs+ ions that are accelerated towards the target held at -8 kV. The Cs+ ions sputter car-
bon atoms and ions from the target that are ionized to C- ions as they pass through a condensed Cs layer on the cathode. Neg-
ative ions at m/z 13 (13C-) and 14 (14C-) are pulsed through an injection magnet or low energy mass spectrometer (B) into a 
tandem electrostatic accelerator (C). Negative C- ions are accelerated towards the high-voltage terminal (+518 kV) in the 
center of the accelerator where they are converted to positive ions, C+ being the most abundant. The high-energy ion beam is 
focused to collide with argon gas electron stripper or a thin carbon foil, 0.02–0.05 μm thick (D) in a collision cell. Molecular 
charged ions such as 13CH- and 12CH2
- do not survive the electron stripping process and are converted to atomic species, and 
14N- ions decay on a femtosecond time-scale. The positive ions are repelled toward the high-energy exit of the accelerator held 
at 0 V. 13C+ and 14C+ ions are separated by momentum using a high-energy analyzing magnet or mass spectrometer (E). The 
beam currents of relatively abundant 12C and 13C are measured with Faraday cups (F). The 14C beam is focused by a quadruple 
and electrostatic cylinder analyzer and the atoms are counted in a gas ionization detector (G). The advantage of a gas ionization 
detector is that it measures energy loss in terms of ΔE/E which facilitates isotope separation. It is possible to optimize the 
detector to the energy-loss separation of the isotope.Journal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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LSC becomes experimentally limiting, while the tech-
nique of AMS has now changed the experimental para-
digm because its extremely sensitive detection limit
virtually removed the previous experimental barriers.
The high sensitivity of AMS indeed affects experimental
designs in several ways. First, the radioisotopic dose can
be reduced to inconsequential levels of radiolysis, hazard-
ous waste streams, and human subject exposure. Sec-
ondly, the chemical dose to a biological system, including
humans of all ages and health status, is minimized to sub-
physiological and sub-toxic doses. This allows a realistic
analysis of the effects arising from low chemical doses. For
example, children and women of child-bearing ages, who
are important targets of increased health-related research,
are suitable subjects at the low doses afforded by AMS
[10,11], since the administration of such low levels of 14C
are considered non-radioactive from a regulatory point of
view. Finally, even if the sampled material needs fraction-
ation to specific biomolecules prior to quantitation, the
sample sizes are reduced to amounts that can be obtained
from well-defined, and often non-invasive procedures.
For a practical AMS measurement, biological samples con-
taining 0.2–5 mg of carbon must be converted to solid
carbon (graphite or fullerene) using a two-step process
[12]. In a quartz tube, and using excess copper oxide
(CuO), the sample's biological carbon is oxidized to CO2.
The CO2 is then reduced to solid carbon by both reduction
with titanium hydride and zinc powder and catalyzation
with either iron or cobalt. Because this process is inde-
pendent of the chemical nature of the sample, it elimi-
nates interference or suppression from other sample
components. Therefore, AMS provides one piece of infor-
mation about the sample of carbon measured: the precise
12C:14C ratio. In AMS, one measures the isotope ratio with
respect to that of a well-known (external) standard in
order to produce an absolute isotope concentration for
the combusted sample [13,14]. With AMS, experimenters
only need the fractional elemental abundance of the sam-
ple and the specific activity of the tracer compound in
order to obtain, in the units most useful for interpretation,
the concentration of the tracer in the sampled material.
The mechanics of an AMS instrument, the mathematical
conversions of the measured values to meaningful "Mod-
ern" values, and the comparisons with LSC are well
reviewed in the literature [3,11,15-17].
For the first time in 1990, sensitive and precise quantita-
tion of 14C was applied to the analysis of biological sam-
ples containing enriched 14C-labeled carcinogens for
toxicology and cancer studies by Turteltaub et al. [18].
Their research quantified chemical binding of the 14C-
labeled carcinogens to DNA at the level of 1 binding in
1011 bases. The benefits of using AMS for the analysis of
samples derived from radiotracer studies with humans
soon became apparent, since AMS produces very specific
quantitation with simple analysis [19]. Any isotope con-
centration greater than the known stable natural 14C back-
ground must arise from an introduced isotope label
("introduced" includes contamination, which must be
carefully controlled and avoided). In the simplest experi-
mental design, there is only one external radioactive
source, perhaps a radiolabeled compound introduced
into the biological system at a specific time. The isotope
ratio of the isolated sample is then easily converted to the
concentration of the labeled compound and its metabo-
lites per g or ml of the analyte.
Not surprisingly, AMS has soon become a tool of choice
for pharmacokinetic analyses [10,11,16]. All the metabo-
lites of the compound that contain the labeled moiety can
be directly quantified in chromatographic separations
without resorting either to secondary standards or to prior
knowledge of metabolic pathways. Although some fluo-
rescent methods quantitate into the amol levels [20,21],
they require derivatization procedures that are not suita-
ble for in vivo tracing, create tracers that are not chemically
equivalent, and are less general in applicability across
many biological systems. Conversely, AMS is specific only
to the labeled compound in any chemical or biological
medium. Such specificity requires neither prior speciation
nor the introduction of either molecular modifications or
internal standards. With AMS, it is possible to conduct
radiotracer studies in human with the administration of
such low levels of 14C [10,11].
The most recent innovation using AMS technology is the
so-called "microdosing" concept [10]. Choosing a drug
for clinical trials from numerous candidates is very much
a hit-and-miss business. Data are gathered from in vitro, in
vivo, and in silico models in order to predict the drug's
behavior in humans but such methods are probably only
about 60% predictive. Presented with a choice of good
candidates, it would be better to take them all into human
subjects. This would, however, be prohibitively expensive,
as each compound would require a significant package of
toxicological safety testing. Alternatively, each candidate
drug could be given to human volunteers at very low lev-
els of a few tens, or at most a hundred μg. At these levels,
only a limited toxicology package is required and in vivo
human data can be acquired for candidate selection [22].
Only AMS has the required sensitivity to conduct such
studies at the low μg level.
In this review, the recent development of AMS methods to
the present day in biomedical/bioanalytical research
where it is being strategically used with high precision (see
Figure 2 for the major applications of AMS discussed here)
will be followed.Journal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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Toxicant/drug metabolism study using AMS
After the first biomedical application of sensitive and pre-
cise quantitation of 14C by AMS in 1990 [18], the tech-
nique has been explored for using animals and for
fractionating tissues, cells and molecules in the study of
metabolism, covalent macromolecule-ligand interactions,
and non-covalent macromolecule-ligand interactions
with amol sensitivity [8-10]. For example, Phillips et al.
reported in 2000 a good application of AMS for these pur-
poses by performing metabolism and macromolecular
binding studies, primarily of environmental toxicants and
toxins, as well as of vitamins in humans at physiological
concentrations [23], which combined two general areas
into an ongoing study of cancer chemoprevention by die-
tary agents. They investigated covalent interactions of
metabolic products with DNA and proteins, both in ani-
mal hosts and in humans.
The heterocyclic amines are compounds that are found in
cooked meat and are potent carcinogens in rodent mod-
els. However, their role in human cancer remains largely
unknown. Using AMS, Felton's group at the Lawrence
Livermore National Laboratory has identified the metab-
olites of [2-14C]2-amino-1-methyl-6-phenylimidazo [4,5-
b]pyridine (PhIP) in humans and the relationships
between the activities of key enzymes involved in PhIP
metabolism and metabolite profiles [24,25]. In addition,
the levels of PhIP adducts on the DNA and blood proteins
of humans and rodents were quantified by AMS [26,27].
Through these works, it has been possible to establish the
scaling factors between animal hosts and humans for
DNA and protein adduct formation, as well as to establish
plasma and urinary biomarkers of PhIP exposure. The
sensitivity of AMS is required to keep both the chemical
and the radiation doses to human volunteers to levels that
do not exceed commonly accepted risks. These works have
led to a follow-on research to establish an AMS-based
assay for quantifying PhIP-protein adducts in humans
and the use of urinary PhIP-metabolites as biomarkers of
PhIP exposure [28,29].
The work with heterocyclic amine carcinogen has been
expanded to the development of chemopreventive strate-
gies for reducing the amount of DNA damage following
carcinogen exposure and to the quantitation of the ability
of certain dietary agents to reduce the levels of DNA
adducts from two heterocyclic amines, PhIP and 2-amino-
3-methylimidazo [4,5-f]quinoline (IQ) [30]. It was found
that chlorophyllin (a stable form of chlorophyll that is
found in green leafy vegetables) and the isothiocyanate
(found in broccoli) caused the greatest adduct reductions
in prostate, liver and colon of rodents, presumably by
modifying the metabolic processes leading to the final
reactive metabolites. Turesky et al. performed a study to
explore the use of coffee as a cancer chemopreventive
agent as well [31]. They studied not only the effect of cof-
fee on the enzymes that metabolize PhIP, but also its util-
ity in reducing PhIP-DNA adduct levels. A 50% decrease
in adduct formation was observed after 24-hour exposure
in the liver of rats on the 5% coffee diet vs. the control
group. An induction of glutathoine S-transferases, which
are involved in the detoxication of HONH-PhIP and its
reactive N-acetoxy intermediate might contribute to this
protective effect of coffee in liver, not in extrahepatic tis-
sues, based upon PhIP-DNA adduct formation. Various
animal models were also used to study covalent binding
levels of toxic compounds, including a quantitation of
chromatin adducts of acrylamide in male germ cells of
mice that was related to pre-implantation abnormalities
in embryos [32]. The sample material available for analy-
sis was so small that AMS quantitation could be the only
reasonable route for obtaining very pure chromatin.
Major applications of AMS in various biomedical investigations discussed in the review Figure 2
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Very recently, AMS was successfully used to measure the
kinetics and repair of DNA adducts formed by two chem-
otherapeutic compounds, carboplatin and oxaliplatin
[33,34]. For carboplatin, AMS was used to measure carbo-
platin-DNA binding in purified genomic DNA and in T24
human bladder cancer cells [34]. The kinetics observed for
the first time for reaction with genomic DNA revealed that
the rate of carboplatin-DNA adduct formation was
approximately 100-fold slower than that reported for the
more potent analog cisplatin, which may explain the
lower toxicity of the compound. In human bladder cancer
cells exposed to carboplatin, AMS allowed a measurement
sensitivity of 1 amol per 10 μg of DNA. In addition, the
rate of oxaliplatin adduction to salmon sperm DNA was
measured, and oxaliplatin-DNA adduct distribution was
further investigated at the nucleoside level by high-per-
formance liquid chromatography (HPLC)-AMS following
enzymatic digestion [33]. Importantly, rates of cellular
drug influx, efflux, DNA damage and DNA repair in cul-
tured platinum-sensitive testicular (833K) and platinum-
resistant breast and bladder (MDA-MB-231 and T24,
respectively) cancer cells incubated with a subpharmaco-
logical dose of oxaliplatin (0.2 μM) were quantified and
differentiated by AMS.
Radiolabeled adriamycin, also known as doxorubicin,
was introduced to MCF-7 human breast cancer cells by
Coldwell et al. [35]. Although adriamycin is an anti-cancer
agent with the widest spectrum of anti-tumor activity,
especially in the treatment of breast cancer and the domi-
nant mechanism of action appears to involve impairment
of topoisomerase IIα activity, the exact mechanism by
which adriamycin exerts its anti-tumor activity is still
uncertain. With many potential alternative mechanisms
of action cited and reviewed, the technology of AMS has
provided the first direct evidence of adriamycin-DNA
adducts at clinically-relevant adriamycin concentrations.
Kwok et al. found dose-dependent binding of orthophe-
nylphenol (OPP) fungicide to proteins in the rat urinary
bladder, but found no significant covalent binding to the
DNA [36]. The observed carcinogenic effect of OPP in the
bladder might be due to the interference of critical cellular
functions through quinone initiated oxidative stress and/
or an interaction between quinones and critical sulfhy-
dryl-containing protein targets resulting in genetic altera-
tions or cell death. The high sensitivity of AMS helps
discard the hypothesis of DNA binding, even at the low
doses administered.
Two studies [37,38] looked at the genotoxicity potential
of benzene by quantifying species and strain differences of
the protein and DNA binding at very low doses and by
testing for histone-specific binding of benzene metabo-
lites using gel separations and MS analysis with AMS
quantitations. It should be noted that no specificity
toward individual histone species was found though pro-
tein adducts of benzene or its metabolites were indicated
by elevated levels of 14C and that these studies used realis-
tic inhalation doses. The incorporation of 14C was largely
proportional to the density of gel staining, giving little evi-
dence that the proteins were specific targets for selective
labeling, implying high reactivity of benzene toward pro-
teins which enables such attack to occur at multiple sites
within multiple targets. In addition, Goldman et al. used
postlabeling to eliminate the need for using a 14C-labeled
compound directly in the biological subject in a study of
benzo-pyrene adduction to DNA [39], where 14C-labeled
acetic anhydride was used to recognize and label
benzo[a]pyrene adducts on DNA.
Liu's group applied AMS to the study of the DNA adduc-
tion of several common 14C-labeled chemicals. One study
shows that the adduction of nitrobenzene is suppressed
by vitamin C, vitamin E, tea polyphenols, and other die-
tary substances [40]. A high-dose level of sodium ben-
zoate (500 mg/kg of body weight) in mice resulted in
higher adduction in the kidney than in the liver. The levels
of DNA-benzoate adducts decayed quite rapidly initially
but persisted at a low level which is relevant to chronic use
of sodium benzoate [41].
The dangers of certain dietary compounds to genetic
material was then expanded to include aflatoxin B1 (AFB1)
adducts as measured in the colon DNA of rats and
humans [42], in which the levels of AFB1-DNA and AFB1-
albumin adducts were investigated by AMS, indicating
that there is a linear relationship between the exposure to
AFB1 and AFB1-albumin adduct formation in rats in a dose
range of 0.16 ng/kg–12.3 μg/kg, and that the protein
adduct levels in the rats are similar to humans.
The human metabolism of atrazine herbicide was traced
in urine as a function of time for one week after a dermal
exposure [43]. A highly polar metabolite, previously
undiscussed, formed the largest single fraction of the
excreted metabolites by the second day and continued at
the same level for one week. These measurements consti-
tuted a "rescue" effort, because the 14C level in the urine
was too low for LSC of the chromatography fractions. The
fractions were easily quantified by AMS, even for a total of
1.7 fmol of 14C loaded on the column in the 7-day post
dose sample.
Boocock et al. identified the human cytochrome enzyme
involved in metabolizing the cancer therapeutic
tamoxifen to reactive states that can lead to DNA adduc-
tion [44]. They also quantified the level of binding
tamoxifen to endometrial and colon DNA in an attempt
to understand the role, if any, of this drug in endometrialJournal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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and colon cancer. They expanded the study to establishing
if tamoxifen binds irreversibly to uterine DNA when given
to women patients who were given a single therapeutic
dose of 14C-labeled tamoxifen citrate orally ~18 hours
prior to hysterectomy or breast surgery [45]. They demon-
strated that after oral administration, tamoxifen forms
adducts in human uterine DNA but at low numbers rela-
tive to those previously reported in women after long-
term tamoxifen treatment where levels, when detected,
ranged from 15,000 to 130,000 adducts/1012 nucleotides.
Neuroscience study using AMS
AMS has been used to study long-term pharmacokinetics,
to identify biomolecular interactions, to determine
chronic and low-dose effects or molecular targets of neu-
rotoxic substances, to quantify transport across the blood-
brain barrier (BBB) and to resolve molecular turnover
rates in the human brain on the time-scale of decades.
Organophosphates, such as diisopropyl fluorophosphates
(DFP), are frequently used as insecticides. DFP has been
previously used as an experimental agent in neuroscience
for its ability to inhibit cholinesterases and induce
delayed peripheral neuropathy [46] and as an ophthalmic
cholinesterase inhibitor in glaucoma treatment [47,48].
The sensitivity of AMS permitted the study of low-level
(sub-toxic) exposure to acutely toxic compounds in vivo
(DFP has an oral LD50 in rat of 1.3 mg/kg). Vogel's group
quantitated low-dose binding of the nerve agent analog,
DFP, to the plasma and brain proteins of mice as a quan-
tifiable biomarker of multiple chemical effects from pre-
exposures of parathion (PTN), permethrin (PER), and
pyridostigmine bromide (PYB) [49]. They found that
brain DFP binding increased by 25–40% under various
pesticide pre-exposure in food, although the plasma bind-
ing concentrations did not change. A cholinergic-derived
induction of NO was hypothesized to increase brain
blood flow, resulting in higher delivery of DFP to the
brain prior to its metabolism by copious plasma and liver
estrases. Pyridostigmine produced a general 15% decrease
in binding, presumably due to lower bioavailability of the
food-delivered toxins arising from increased intestinal
peristalsis. The effect on the permeability of the BBB to
low doses of pesticide mixtures was also investigated
using 14C-labeled DFP as a quantifiable probe of effects
due to unlabeled PTN, PER and PYB separately and in
conjunction [49]. The study concluded that if the increase
in brain DFP level were due to increased permeability of
the BBB, other toxins or pathogens might also induce
increased BBB permeability with low pesticide exposure,
and that the sensitivity of AMS allowed the probing of
specific biochemical pathways using physiological doses,
which did not perturb the natural system of the model
animal.
After the emergence of Gulf War Syndrome in veterans of
the 1991 Gulf War, synergistic exposures to combinations
of esterase inhibitors were a hypothesized contributor,
and AMS was used to examine the effect of chronic expo-
sure to PYB (7.75 mg/kg per day in chow) on acute doses
of 14C-labeled PER (4.75 μg/kg). At 1 h after dosing, the
amount of PER in brain and spinal cord was reduced by
30% for animals receiving PYB. At 24 h, there was no dif-
ference in PER in the brain but the spinal cord had 70%
less PER with PYB exposure. The levels of PER in the
plasma was the same for each dose group. The sensitivity
of the measurement was pg/g per equivalents in dissected
tissue. Since PER and PYB are not direct competitors for
enzyme binding, and the qualified effect is too large for
competitive inhibition at these doses, a physiological
effect such as decreased bioavailability is suggested.
It is estimated that more than 90% of degenerate demen-
tias are proteinopathies. i.e. caused by abnormal protein
aggregation [50]. In Alzheimer's disease (AD), these are
primarily different amyloid β (Aβ) peptides and a hyper-
phosphorylated form of the tau protein [51], whereas α-
synuclein is implicated in Parkinson's disease, dementia
with Lewi bodies and other forms of dementia [52,53].
Although numerous contributing factors have been iden-
tified, the etiology of these diseases is generally poorly
understood. The bomb pulse of 14C (Figure 3) was used to
determine the average date of formation of the major his-
topathological features in AD brain: extracellular senile
plaques (SP), composed primarily of Aβ peptide, and
intracellular neurofibrillary tangles (NFT), composed of
paired helical filaments containing hyperphosphorylated
tau proteins [51]. The changing 14C level of contemporary
carbon was also used to determine the carbon 'age' of nor-
mal brain tissue (1.4 years). The SP and NFT structures
have a much slower carbon turnover rate than normal tis-
sue and are not in a formation/degradation equilibrium.
The study showed that the average age of isolated SP and
NFT was significantly greater than normal tissue from the
same subjects (SP by 9.8 ± 4.9 years and NFT by 9.4 ± 3.8
years). Although a clear and consistent pattern of forma-
tion of NFT and SP could not be formulated from the
small number of analyzed subjects, in four out of six cases,
average SP and NFT or both predated the onset of symp-
toms by as long as 9 years. It is expected that more effi-
cient isolation techniques that can accommodate smaller
specimens from specific brain regions will produce more
consistent patterns of information and such studies could
provide valuable information on the etiology and pro-
gression of AD and other neurodegenerative proteinopa-
thies.
Calcium concentration and its spatial localization and
dynamics are important in many neuronal processes, such
as signaling, long-term potentiation and depressionJournal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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[54,55], dendrite [56], and spine formation [57].
Although very sensitive fluorescent methods for quantify-
ing [Ca2+] in vivo and in real time are well established
[58,59], they require careful calibration and cannot
directly distinguish between different sources of Ca2+. Fur-
thermore, the Ca2+-sensitive dyes add a significant exoge-
nous buffer capacity and distort the amplitude, time
course and spread of [Ca2+] signals. Lin et al. in 2004
improved the sample chemistry required to extract cal-
cium quantitatively from plasma, urine, and saliva using
schemes that greatly increased the sample throughput as
well as quality of the samples [60]. They studied 41Ca
quantitation with AMS to access bone health for humans
and dietary protein effects on bone resorption. It is
expected to quantify changes in bone resorption using
41Ca arising from 3H- or 14C-labeled pharmaceuticals. The
value of 41Ca quantitation for cancer, aging, and nutritive
research is becoming better recognized, and AMS tech-
nique will maintain its present dominance in high
throughput measurement of this important biomedical
tracer isotope.
Pharmacokinetic study using AMS
The benefits of using AMS for the analysis of samples
derived from radiotracer studies include pharmacokinetic
studies with humans. The maximum radioactive dose that
can be administered to humans depends on the residence
time in the body and whether it is accumulated in specific
tissues. Under certain circumstances, i.e. when there is a
long pharmacokinetic half-life, the amount of radioactiv-
ity that can be administered is below the capabilities of
LSC. Since the advent of biomedical AMS, it has been pos-
sible to conduct radiotracer studies in humans, with the
administration of such low levels of 14C that they are,
from a regulatory point of view, considered non-radioac-
tive.
Furthermore, in the development of a new drug, there
may be a number of candidate compounds available to go
forward into clinical trials. The classical selection process
involves conducting a series of modeling experiments
using in vitro, cell-based or in silico techniques and some
experiments with small numbers of laboratory animals.
Through a process known as allometric scaling, a predic-
tion is made of the pharmacokinetics of the candidate
drug in humans. However, allometric scaling has occa-
sionally failed to adequately predict the behavior of the
drug in humans. In an ideal case, all the candidate drugs
would be dosed to humans and selection made on the
basis of true in vivo data. Practically, however, such an
Bomb curve used for dating recent biological materials Figure 3
Bomb curve used for dating recent biological materials. The levels of 14C in the atmosphere have been relatively stable 
over long time periods, with the exception that atmospheric nuclear weapons tests in 1955–1963 added significant amounts of 
14C to the environment. *The age of the biological material is calculated based on an assumption that the organism's biosynthe-
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approach would be prohibitively expensive due to the
enormous amount of preclinical toxicology safety testing
required.
An alternative approach, therefore, has been suggested
[10] where very small amounts of drugs, in the microgram
range, are administered. With such trace doses, the toxico-
logical safety tests required are vastly reduced [22]. Hence,
it is possible to dose a range of candidate drugs to humans
and select the one with optimum pharmacokinetics to
take forward for further clinical evaluation. The major bar-
rier to this approach is the extremely sensitive methods of
detection are required in order to quantitate the drug and
its metabolites in plasma and excreta following the
administration of such a small microdose.
AMS, an innovation technology for this purpose, has
made it possible to administer such low amounts of 14C-
labeled candidate drugs to humans and still retain suffi-
cient levels of analytical sensitivity to determine its metab-
olism and pharmacokinetics, even though the amount of
radioactivity that can be administered to humans is lim-
ited owing to the radiation exposure, not surprisingly.
This technique is, however, very much in its infancy and it
is not known, for the majority of drugs, whether the phar-
macokinetics will be sufficiently linear so that the phar-
macokinetics observed at the microdose will be predictive
of those at the therapeutic dose. It is important, therefore,
to study comparative pharmacokinetics of a drug candi-
date at high and low doses to establish the validity of the
"microdosing" concept, that is, a human microdosing
study comprises the administration of a sub-pharmaco-
logical/sub-therapeutic dose of novel drug candidate(s) in
order to gain essential pharmacodynamic and pharma-
cokinetic information [10,11]. To date, a major trial is
underway financed by a group of pharmaceutical compa-
nies to test this theory.
In 2004, Sandhu et al. reported [61] the first description of
the full pharmacokinetic profile of a drug candidate
assessed and of the comparisons of the kinetics of a phar-
maceutical compound at pharmacological versus sub-
pharmacological doses employing microdosing strategies,
in order to address the unresolved issue of whether the
pharmacokinetics determined following a microdose are
representative of those following a conventional (phar-
macological) dose. They successfully validated and uti-
lized the technique of AMS to study the pharmacokinetics
and disposition in dogs of a preclinical drug candidate
after oral and intravenous administration. They empha-
sized in the paper that only the exceptional sensitivity of
AMS can provide a pharmacokinetic profile of the drug
candidate, even following a microdose, which reveals
aspects of the disposition of the agent that are inaccessible
by conventional techniques. Li et al., on the other hand,
designed a new drug delivery microelectromechanical sys-
tems (MEMS) to deliver tracer molecules as well as a ther-
apeutic agent in vivo and evaluated their spatial and
temporal release profiles using AMS [62].
Nutritional study using AMS
It is becoming apparent that all humans do not identically
respond to either diets or medicines, so their needs differ
according to differences in their genetic information and
physiological status. AMS may be particularly useful in
obtaining accurate spatial information and low-level
detection of essential and nonessential bioactive food
components (nutrients) and their metabolites, and in
enhancing the understanding of the impact of nutrient/
metabolite and biomolecular interactions. The fate and
distribution of vitamins at physiological concentrations
within healthy humans of all ages, for instance, had not
been quantified prior to the use of AMS [63]. Vitamin
research was performed including mathematical statistics
and modeling using the high density human kinetic data
to explore the parameter space of kinetic modeling
[64,65].
The initial study involved sub-physiological doses of folic
acid, which is especially important to the health of young
mothers, but which had been studied only in elderly ill
human subjects. AMS tracing doses contain a few hundred
nanoCurie of 14C or less, even for highly recirculated
nutrient chemicals, exposing the volunteer subject to less
radiation damage than is obtained within 10 minutes in a
commercial air flight. This is a commonly accepted level
of radiation exposure, even among pregnant women, to
whom a better understanding of their true folate needs is
important. An isotopic form of folate was required to dis-
tinguish the dosed material from the greater amount of
endogenous folate, but stable isotopic approaches have
not been able to follow single physiologic doses for more
than a few days in human volunteers [66]. Other studies
used chronic isotopic dosing to obtain turnover and
kinetic elimination measures, but do not provide detailed
kinetic profiles [67]. The initial data quickly showed that
folate was an effective label for the study of red blood cell
production, lifetime and elimination [43], which has
been approached by hematologists about the possibility
of using this pulse-chase labeling mode to study the red
blood cell lifetimes in disease states such as sickle-cell ane-
mia or malaria. Lin et al. summarized the 6-months phar-
macokinetic data from 13 human subjects with a median
age of 24, including 7 women and suggested a connection
between liver disease and folate deficiency, as revealed by
detailed compartmental modeling of the entire high-den-
sity data sets from all 13 subjects [60,68]. These works
may explain the world's highest incidence of neural tube
birth defects along the southern Rio Grande [69] as arising
from the endemic levels of hepatitis [70], rather than theJournal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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apparently unrelated low folate intake [71], or common
polymorphisms within the Hispanic population [72].
Relations between cirrhosis and homocystenemia, a risk
factor in heart disease, also derived from the large recy-
cling of demethylated folate through bile and back into
the liver for remethylation [73,74].
The small samples used in AMS can provide high data
density. AMS has the high sensitivity for long-term kinetic
analysis to give detailed elimination information. Thus,
only AMS could result in a model sufficiently detailed to
reveal the hidden variables possibly responsible for these
health effects. Dueker et al. showed that naturally pro-
duced β-carotene could be used at low doses to judge the
vitamin A potential of carotene [75]. Reverse-phase HPLC
was used with AMS to quantify plasma metabolites of the
carotene in 99 hours after dosing. An unidentified acidic
metabolite, possibly an epoxide, was found to comprise
15% of the circulating acidic fraction, and the metabolism
of β-carotene to retinol and retinyl esters was surprisingly
enhanced by a vitamin A supplementation that should
decrease the need for carotene-derived retinal [76,77]. An
increase in carotene absorption at the expense of intesti-
nally produced retinyl esters was also found.
Other important research using AMS
Non-covalent equilibrium binding was quantified by
AMS in two studies seeking to develop more sensitive
immunoassays (IA) [78,79]. Lu et al. developed an AMS-
IA to one species of the parathyroid hormone related pro-
tein that is a biomarker of prostate cancer [78], and Shan
et al. showed that AMS increased sensitivity and quantita-
tion over already sensitive ELISA-IA's for atrazine and
dioxin without resulting in a waste stream that exceeded
the government's definitions of radioactive materials [79].
These studies set the stage for further development of non-
covalent labeling strategies that are not as straightforward
as the previously listed covalent binding work, and may
serve as models for the development of sensitive and
"nonradioactive" IA for peptides, including polypeptide
tumor markers.
The two IA efforts above are also forms of postlabeling
recognition of specific protein moieties and chemicals in
biological solutions. Miyashita et al., on the other hand,
demonstrated highly sensitive protein sequencing by
Edman degradation, which is an impetus for developing
methods of analyzing extremely small amounts of biolog-
ical systems [80]. Their method is expected to be applica-
ble to the sequencing of proteins from cell culture and
illustrates a path to more general methods for determin-
ing N-terminal sequences with high sensitivity.
Biomedical applications of AMS were expanded to the
study of DNA damage/repair. An AMS method was devel-
oped for rates of in vivo incorporation and repair of an 8-
oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a well
known DNA oxidative damage biomarker [81-83]. These
studies were performed to determine if 8-oxodG can be
phosphorylated and incorporated into DNA from oxida-
tion of the nucleotide pool. The composition of the radi-
olabeled nucleotides incorporated into DNA from the
14C-labeled 8-oxodG dosed cells was determined by nucl-
eoside digestion followed by HPLC. Digestion of the DNA
to nucleosides followed by separation with HPLC allowed
determination of the composition of the radiolabeled
nucleosides in the purified DNA. Each chromatogram
shows a single peak that coelutes with an authentic stand-
ard of 8-oxodG. The single peak observed is also confir-
mation of the quality of the DNA digest and purification
conditions, which were optimized to avoid artifactual 8-
oxodG oxidation. The data collectively indicate that in the
cells studied the nucleotide pool can be a significant
source of 8-oxodG for incorporation into genomic DNA.
Importantly, it was found that the rate of incorporation of
8-oxodG is approximately equal to that of dG and that the
maximum concentration achieved was ~2 per 107 normal
nucleotides, a level approaching that of background 8-
oxodG levels in most cell types. Interestingly, it was unex-
pectedly found that radiocarbon from 14C-labeled 8-
oxodG was also incorporated into RNA, which was fol-
lowed by a mechanistic analysis of several pathways by
which 8-oxodG is converted to nucleotide triphosphates
and incorporated into both DNA and RNA [81], allowing
to propose an 8-oxodG metabolic mechanism in MCF-7
human breast cancer cells, as illustrated in Figure 4. A new
approach is now opened to the mechanistic study of
measuring the kinetics of small molecule fates at a very
low level of detection with high precision and observing
the initiating events in the nucleobase modification that
lead to carcinogenesis or other diseases.
AMS was also used as a core technique to verify that 5'-
methylthioinosine is an active nucleic acid precursor in
Plasmodium falciparum which is unable to synthesize
purine bases and relies on purine salvage and purine recy-
cling to meet its purine needs [84]. To understand the
purine pathways of malaria, they characterized the activi-
ties of adenosine deaminase and purine nucleoside phos-
phorylase from P. falciparum which have catalytic
specificities that allow them to use methylthiopurines and
therefore to function in both purine salvage and methyl-
thiopurine recycling. By using AMS, they showed this
pathway is active in P. falciparum cultured in human eryth-
rocytes.
Retrospective birth dating of cells in humans was achieved
based on the AMS measurement, which is a generally
applicable strategy that can be used to measure cell turno-
ver in man under physiological and pathological condi-Journal of Biomedical Science 2009, 16:54 http://www.jbiomedsci.com/content/16/1/54
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tions [85]. They took advantage of the fact that testing of
nuclear weapons resulted in a dramatic global increase in
the levels of the isotope 14C in the atmosphere, followed
by an exponential decrease after 1963, as shown in Figure
3[86-88], and they showed that the level of 14C in
genomic DNA closely parallels atmospheric levels and can
be used to establish the time point when the DNA was
synthesized and cells were born. They also found that the
strategy can be used to determine the age of cells in the
cortex of the adult human brain leading to the conclusion
that whereas nonneuronal cells are exchanged, occipital
neurons are as old as the individual, supporting the view
that postnatal neurogenesis does not take place in this
region.
In addition to the novel forensic application of AMS
above, the age at death of individuals, an important step
in their identification, was also established with high pre-
cision by AMS analysis of dentition [89]. It was demon-
strated that the amount of radiocarbon present in tooth
enamel as a result of nuclear bomb testing is a remarkably
accurate indicator of when a person was born, since the
enamel of individual teeth contains 0.4% carbon and
there is no turnover of enamel after it has been laid down,
i.e. the 14C concentration reflects that in the atmosphere at
the time of enamel formation. They, therefore, measured
the  14C content of tooth enamel and related it to the
known concentrations in the atmosphere in different
years to establish the year of tooth formation. The date
was then related to the known age for enamel deposition
of individual teeth to establish the person's year of birth,
resulting in a remarkably precise estimate of age for 22
individuals (R2 = 0.99). The average systematic deviation
from the correct value was +0.2 years, and the average
absolute error for individual measurements was 1.6 ± 1.3
years, indicating that the precision is substantially higher
than that obtained by other available methods.
The technology of AMS has been utilized to establish the
dynamics within the stable population of adipocytes in
adults, by measuring adipocyte turnover and analyzing
the integration of 14C derived from nuclear bomb tests in
genomic DNA [85,90]. Spalding et al. demonstrated using
AMS that approximately 10% of fat cells are renewed
annually at all adult ages and levels of body mass index,
although the number of adipocyte is set during childhood
and adolescence. Their results suggest that neither adi-
pocyte death nor generation rate is altered in early onset
obesity, and that a tight regulation of fat cell number in
this condition during adulthood.
Proposed mechanism of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG, a well known DNA oxidative damage biomarker)  metabolism in MCF-7 human breast cancer cells, where PNP stands for purine nucleoside phosphorylase, HGPRT for hypoxan- thine-guanine phosphoribosyltransferase, RNA Pol for RNA polymerase, DNA Pol for DNA polymerase, RR for ribonucle- otide reductase, and BER for base excision repair, respectively Figure 4
Proposed mechanism of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG, a well known DNA oxidative damage 
biomarker) metabolism in MCF-7 human breast cancer cells, where PNP stands for purine nucleoside phos-
phorylase, HGPRT for hypoxanthine-guanine phosphoribosyltransferase, RNA Pol for RNA polymerase, DNA 
Pol for DNA polymerase, RR for ribonucleotide reductase, and BER for base excision repair, respectively. 
MTH1 is a pyrophosphatase capable of cleaving the pyrophosphate either from 8-oxodGTP or 8-oxoGTP, thus preventing the 
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For practical purposes, rapid methods have been devel-
oped to convert organic species into forms compatible
with direct introduction to the spectrometer for 14C anal-
ysis to perform the AMS measurements more efficiently
[12]. Ognibene et al. developed a high throughput modi-
fication of the reduction stage for carbon sample prepara-
tions. The technique uses custom-made septa-sealed
reaction vessels for the trapping, purification, and reduc-
tion of combustion gases to the desired elemental carbon
on an iron-group catalyst. The combustion gases can
come from sealed combustion tubes that are the most effi-
cient process for large numbers of mg-sized samples.
Conclusions and future prospects
While the initial themes of biomedical research with AMS
involved primarily the kinetics and binding of carcino-
genic toxins and focused on toxicokinetics and toxin
metabolism with new initiatives in nutrition and immu-
noassays, scientists have now expanded the study of kinet-
ics and dynamics directly in humans for disease [91,92],
nutritional [75], and pharmaceutical [16] research, since
AMS is now a proven sensitive and robust method for
quantifying rare isotopes in biological systems. Moreover,
AMS has been utilized for the detection of biomarkers or
molecular targets of relevance to nutrition and cancer and
other chronic diseases. This opens up the whole area of
biomarker studies where currently only changes to the
size of a metabolic pool are measured. For example, a
decrease in a metabolic biomarker might be due to
increased catabolism or decreased anabolism. Using a
trace dose of 14C-labeled precursor, the turnover rates of
the biomarker could be determined without unduly
exposing the volunteers to adverse levels of radioactivity.
In theory, any and all endogenous components of a bio-
logical system can be quantified by versatile AMS coupled
with amol radiolabeled-isotope detection capability if
that system is uniformly labeled by an isotope. Under this
condition, all structural, signaling, and nourishing com-
ponents become quantifiable at amol levels by AMS. Such
an approach depends on quantitative isolation of the cho-
sen components from other isotopically labeled materi-
als. Cultures can be commonly grown on isotopically
enriched substrates, usually to produce specific proteins
or lipids for further tracing experiments. More frequently,
specifically labeled precursors can be added to cultures to
enhance the isotopic signal of chosen components. These
isotopic enrichments are akin to tracing specific com-
pounds that cannot reveal the entire biochemical balance
of a system. Biomolecules that are stable over those 20 to
50 years can also be quantified as being retained from a
uniformly labeled system. Any biochemical pathway can
be virtually quantified by AMS if a sufficiently specific
labeling procedure can be found. It is also expected quan-
titative postlabeling strategies can be developed for oxida-
tive and other molecular modifications or functions as
examples of AMS application to a very broad field of bio-
medical research. The unique analytical methods are
expected to provide the scientific proof-of-principle
framework that will proceed through increasing levels of
complexity, to broaden the biomedical applications of
AMS to problems in biochemistry, cell biology, develop-
mental biology, pharmacology, immunology and others.
The knowledge obtained is also expected to be combined
with other biological studies to achieve more complete
pictures of several important biological processes.
Although use of these techniques was not widespread
because of the high instrumentation costs of commer-
cially available systems and the need for qualified physi-
cists to operate the instrument (at the beginning of the
new millennium there were, world-wide, approximately
50 labs engaged in AMS research), the situation is now far
improving. At present, there are several companies for the
commercial exploitation/analysis of AMS and it is also
expected that the instrumentation costs will be less than $
2 M.
AMS has been called an enabling technology, and espe-
cially AMS for 14C analysis has become more accessible
and inexpensive, making the biomedical application of
AMS no more difficult than other tracing and quantifying
methods now used in routine biomedical research. There
are likely to be many more applications to biomedical sci-
ence for this technology in the future, so far never-
thought-of.
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